By Kristen Perosino
Congress is currently considering important legislation to improve drug and medical device safety and strengthen scientific integrity at the Food and Drug Administration (FDA).Â Both the House (H.R. 2900) and Senate (S. 1082) versions contain provisions that should be adopted in the final bill to better protect public health.Â One such provision is Title V Section 501 of the Senate bill regarding the right of FDA scientists to publish their research.Â This language, which amends the Federal Food, Drug, and Cosmetic Act, adds the following wording to the policy on the review and clearance of scientific articles published by FDA employees:
(a) Definition- In this section, the term âarticleâ means a paper, poster, abstract, book, book chapter, or other published writing.
(b) Policies- The Secretary, through the Commissioner of Food and Drugs, shall establish and make publicly available clear written policies to implement this section and govern the timely submission, review, clearance, and disclaimer requirements for articles.
(c) Timing of Submission for Review- If an officer or employee, including a Staff Fellow and a contractor who performs staff work, of the Food and Drug Administration is required by the policies established under subsection (b) to submit an article to the supervisor of such officer or employee, or to some other official of the Food and Drug Administration, for review and clearance before such officer or employee may seek to publish or present such an article at a conference, such officer or employee shall submit such article for such review and clearance not less than 30 days before submitting the article for publication or presentation.
(d) Timing for Review and Clearance- The supervisor or other reviewing official shall review such article and provide written clearance, or written clearance on the condition of specified changes being made, to such officer or employee not later than 30 days after such officer or employee submitted such article for review.
(e) Non-Timely Review- If, 31 days after such submission under subsection (c), the supervisor or other reviewing official has not cleared or has not reviewed such article and provided written clearance, such officer or employee may consider such article not to have been cleared and may submit the article for publication or presentation with an appropriate disclaimer as specified in the policies established under subsection (b).
Information sharing is an essential component in science.Â FDA scientists should be able to conduct research and publish findings without fear of retribution.Â However, a recent survey of FDA scientists suggests that the FDA does not presently offer this open environment.Â Thirty-six percent of the scientists surveyed felt that they could not express any concerns about public health within the FDA without fear of retaliation.Â Forty percent reported that they could not express these concerns publicly without the same reservations.Â The atmosphere within the agency doesnât appear to have changed much since Dr. David Graham, a 20 year veteran FDA scientist, released his 2004 testimony detailing his experience inside the FDA.Â After conducting a large, three-year epidemiologic study, Dr. Graham and other scientists concluded that high-dose Vioxx significantly increased the risk of heart attacks and sudden death.Â The study was labeled by senior management at the Office of Drug Safety as âa scientific rumor.âÂ Moreover, the scientists received pressure from these senior managers to change their conclusions.Â Dr. Graham describes his attempt to publish the results of the Vioxx study:
Finally, we wrote a manuscript for publication in a peer-reviewed medical journal. Senior managers in the Office of Drug Safety have not granted clearance for its publication, even though it was accepted for publication in a very prestigious journal after rigorous peer review by that journal. Until it is cleared, our data and conclusions will not see the light of day in the scientific forum they deserve and have earned, and serious students of drug safety and drug regulation will be denied the opportunity to consider and openly debate the issues we raise in that paper.
How many thousands of lives could have been saved had Dr. Graham and his peers been able to publish their research?Â In an agency responsible for protecting public health, any suppression (or distortion) of science can have dangerous consequences.Â We have already seen evidence of this in the Vioxx tragedy, regarded as the greatest drug safety catastrophe to date, and also in the highly publicized safety problems surrounding Ketek and Avandia.Â With public confidence in the FDA fading, it is clear that federal efforts are needed to ensure that sound science is brought back to the forefront of decision making at the FDA.Â Therefore, scientists should be not only allowed, but encouraged to share scientific results with colleagues as well as the public.Â The right of FDA employees to be able to publish in scientific journals or speak at scientific forums must be clearly established and protected.
Part of the FDAâs mission is to advance public health by âhelping the public get the accurate, science-based information they need to use medicines and foods to improve their health.âÂ FDA scientists are expected to provide this data.Â They should be able to do so without constraints, in order for the public to make truly informed decisions about their health and wellbeing.
Kristen Perosino works for the Project on Scientific Knowledge and Public Policy and is an MPH candidate at George Washington University’s School of Public Health.
4 thoughts on “FDA Scientists and the Right to Publish”
“greatest drug safety catastrophe to date”
Really? Worse than Herion or Thalidomide? What makes it worse?
Dr. Graham calls Vioxx “the single greatest drug safety catastrophe in the history of this country or the history of the world” in his testimony. He estimates that between 88,000 and 139,000 Americans experienced heart attack or sudden cardiac death caused by Vioxx. This exceeds the number of people affected by other historical “drug disasters” such as thalidomide.
Thank you for answering the question Kristen.
Despite this however erudite David Graham’s opinion is, it does not necessarily translate into a general opinion that Vioxx is the worst drug disaster is history. He might be right. However reading the text gives the impression that this was some sort of general consensus position in medical science rather than an opinion given by one person with considerable expertise. I guess I was looking for a citation to a published paper rather than a quotation.
I can’t think of a worse presciption drug other than much older drugs that are now drugs of abuse (Cocaine, Herion, Methamphetamine). Lets hope methylphenidate isn’t such a similar timebomb.
Thalidomide involved “criminal” lying by the drug company that made it. The drug company fielded all the health questions from all over the world and lied to each doctor that they had not had bad reports from any other country. Read “Thalidomide and the power of the drug companys”
Unfortunately now the drug companys have in my view perfected “lying” to the regulator. For example if your new drug kills more people than an existing drug “B”, just say drug B has a protective effect and dont have a “no drug taken” control group for a base line. ( they actually did this)
Safest practice dont take a new drug until it is at least 5 years old,
this seems to be how long it takes for the deaths to mount up to the point where the FDA has to recall the killer drug.
research the approval of aspartame / nutrasweet to see how broken the approval process is ( Donald Rumsfield , yeah that one, was the CEO of the company that makes it, so this may never be fixed ) IT is the only time the FDA has launched CRIMINAL charges against a drug company executives. (not Donald though if i remember corrrectly